PHAXIAM THERAPEUTICS S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.925 EUR | +1.74% |
|
-1.18% | -36.41% |
| Sales 2024 * | 1.05M 1.13M 90.36M | Sales 2025 * | 1.6M 1.72M 138M | Capitalization | 17.62M 18.93M 1.52B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | 1M 1.07M 86.06M | EV / Sales 2024 * | 17.2 x |
| Net Debt 2024 * | 450K 484K 38.73M | Net Debt 2025 * | 10.55M 11.34M 908M | EV / Sales 2025 * | 17.6 x |
| P/E ratio 2024 * |
-2.06
x | P/E ratio 2025 * |
-3.05
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| 1 day | +1.74% | ||
| 1 week | -1.18% | ||
| Current month | -1.18% | ||
| 1 month | -1.35% | ||
| 3 months | -20.30% | ||
| 6 months | -36.14% | ||
| Current year | -36.41% |
1 week
2.86
2.96
1 month
2.862.97
Current year
2.784.70
1 year
2.6011.70
3 years
2.6075.80
5 years
2.60114.60
10 years
2.60402.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 22/06/23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 22/06/23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 22/06/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 22/06/23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 22/06/23 |
Gil Beyen
BRD | Director/Board Member | 62 | 22/06/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/05/24 | 2.9 | -0.85% | 4,462 |
| 06/05/24 | 2.925 | +1.74% | 2,704 |
| 03/05/24 | 2.875 | -1.54% | 7,054 |
| 02/05/24 | 2.92 | -1.35% | 1,070 |
| 30/04/24 | 2.96 | +0.17% | 663 |
End-of-day quote Euronext Paris, May 05, 2024
More quotes
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
14/05/2024
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.9
EUR
Average target price
6.85
EUR
Spread / Average Target
+136.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.41% | 18.99M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +6.72% | 23.47B | |
| -13.89% | 21.9B | |
| -6.64% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- PHXM Stock
